Latest From Ushio Inc.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced July through August 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced June-July 2015.
Patient safety concerns and limited payments for hospital-acquired conditions (HACs) are fueling double-digit growth in the multibillion-dollar market for point-of-care vascular imaging devices as hospitals increasingly look to these vein-viewing technologies to improve patient satisfaction and minimize complications associated with venous access procedures.
- Infection Control-Sterilization
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Ushio Inc.
- Senior Management
- Contact Info
Phone: (81) 3 3242 1811
6-1 Otemachi 2-chrome
Asahi Seimei Ot
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.